FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2889908907> ?p ?o ?g. }

• W2889908907 endingPage "1597" @default.
• W2889908907 startingPage "1587" @default.
• W2889908907 abstract "Background Pulmonary arterial hypertension (PAH) is characterised by remodelling in vascular smooth muscles, and switching from contractile (differentiated) to synthetic (dedifferentiated) phenotype. This study aimed to investigate the effect of a mutated caveolin-1 (Cav1F92A) gene from bone marrow mesenchymal stem cells (rBMSCs) on phenotypic switching in the smooth muscle cells during PAH. Methods Human pulmonary smooth muscle cells (HPASMCs) were treated with monocrotaline (MCT,1 μM), and co-cultured with Cav1F92A gene modified rBMSCs (rBMSCs/Cav1F92A). The nitric oxide (NO) production, cell adhesion, cell viability and inflammatory cytokines expression in rBMSCs was measured to evaluate the survival rate of rBMSCs and the changes of inflammatory cytokines. The concentration of NO/cGMP (nitric oxide/Guanosine-3',5'-cyclic monophosphate), the tumour necrosis factor-alpha (TNF-α), transforming growth factor-beta1 (TGF-β1) mRNA, the expression of contractile smooth muscle cells (SMCs) phenotype markers (thrombospondin-1 and Matrix Gla protein, MGP), the synthetic SMCs phenotype markers (H-caldesmon and smooth muscle gene SM22 alpha, SM22α), cell migration and the morphological changes in rBMSCs/Cav1F92A co-cultured HPASMCs were investigated. Results Cav1F92A increased NO concentration, cell adhesion, cell viability, anti-inflammatory cytokines interleukin-4 (IL-4), and interleukin-10 (IL-10), but decreased the inflammatory cytokines interleukin-1α (IL-1α), interferon-γ (INF-γ) and TNF-α expression in rBMSCs. rBMSCs/Cav1F92A activated the NO/cGMP, down-regulated TNF-α, TGF-β1, thrombospondin-1 and MGP expression, up-regulated SM22α and H-caldesmon expression, restored cell morphology, and inhibited cell migration in MCT treated HPASMCs. Conclusions rBMSCs/Cav1F92A inhibits switching from contractile to synthetic phenotype in HPASMCs. It also inhibits migration and promotes morphological restoration of these cells. rBMSCs/Cav1F92A may be used as a therapeutic modality for PAH. Pulmonary arterial hypertension (PAH) is characterised by remodelling in vascular smooth muscles, and switching from contractile (differentiated) to synthetic (dedifferentiated) phenotype. This study aimed to investigate the effect of a mutated caveolin-1 (Cav1F92A) gene from bone marrow mesenchymal stem cells (rBMSCs) on phenotypic switching in the smooth muscle cells during PAH. Human pulmonary smooth muscle cells (HPASMCs) were treated with monocrotaline (MCT,1 μM), and co-cultured with Cav1F92A gene modified rBMSCs (rBMSCs/Cav1F92A). The nitric oxide (NO) production, cell adhesion, cell viability and inflammatory cytokines expression in rBMSCs was measured to evaluate the survival rate of rBMSCs and the changes of inflammatory cytokines. The concentration of NO/cGMP (nitric oxide/Guanosine-3',5'-cyclic monophosphate), the tumour necrosis factor-alpha (TNF-α), transforming growth factor-beta1 (TGF-β1) mRNA, the expression of contractile smooth muscle cells (SMCs) phenotype markers (thrombospondin-1 and Matrix Gla protein, MGP), the synthetic SMCs phenotype markers (H-caldesmon and smooth muscle gene SM22 alpha, SM22α), cell migration and the morphological changes in rBMSCs/Cav1F92A co-cultured HPASMCs were investigated. Cav1F92A increased NO concentration, cell adhesion, cell viability, anti-inflammatory cytokines interleukin-4 (IL-4), and interleukin-10 (IL-10), but decreased the inflammatory cytokines interleukin-1α (IL-1α), interferon-γ (INF-γ) and TNF-α expression in rBMSCs. rBMSCs/Cav1F92A activated the NO/cGMP, down-regulated TNF-α, TGF-β1, thrombospondin-1 and MGP expression, up-regulated SM22α and H-caldesmon expression, restored cell morphology, and inhibited cell migration in MCT treated HPASMCs. rBMSCs/Cav1F92A inhibits switching from contractile to synthetic phenotype in HPASMCs. It also inhibits migration and promotes morphological restoration of these cells. rBMSCs/Cav1F92A may be used as a therapeutic modality for PAH." @default.
• W2889908907 created "2018-09-27" @default.
• W2889908907 creator A5003324293 @default.
• W2889908907 creator A5018666743 @default.
• W2889908907 creator A5028454371 @default.
• W2889908907 creator A5038067799 @default.
• W2889908907 creator A5052004020 @default.
• W2889908907 creator A5064314277 @default.
• W2889908907 creator A5066782203 @default.
• W2889908907 creator A5073216396 @default.
• W2889908907 creator A5078162124 @default.
• W2889908907 creator A5082068143 @default.
• W2889908907 date "2019-10-01" @default.
• W2889908907 modified "2023-09-26" @default.
• W2889908907 title "Dissecting Molecular Mechanisms Underlying Pulmonary Vascular Smooth Muscle Cell Dedifferentiation in Pulmonary Hypertension: Role of Mutated Caveolin-1 (Cav1F92A)-Bone Marrow Mesenchymal Stem Cells" @default.
• W2889908907 cites W1483720742 @default.
• W2889908907 cites W1486973386 @default.
• W2889908907 cites W1755496226 @default.
• W2889908907 cites W1971218073 @default.
• W2889908907 cites W1995605351 @default.
• W2889908907 cites W2012694124 @default.
• W2889908907 cites W2020764743 @default.
• W2889908907 cites W2024338340 @default.
• W2889908907 cites W2030497132 @default.
• W2889908907 cites W2045175965 @default.
• W2889908907 cites W2055348159 @default.
• W2889908907 cites W2058910543 @default.
• W2889908907 cites W2061561342 @default.
• W2889908907 cites W2062002285 @default.
• W2889908907 cites W2070114011 @default.
• W2889908907 cites W2070743752 @default.
• W2889908907 cites W2087739255 @default.
• W2889908907 cites W2089743065 @default.
• W2889908907 cites W2092266379 @default.
• W2889908907 cites W2094818701 @default.
• W2889908907 cites W2108373798 @default.
• W2889908907 cites W2111662626 @default.
• W2889908907 cites W2129033842 @default.
• W2889908907 cites W2135943414 @default.
• W2889908907 cites W2142610113 @default.
• W2889908907 cites W2144106355 @default.
• W2889908907 cites W2151475873 @default.
• W2889908907 cites W2155448526 @default.
• W2889908907 cites W2170478368 @default.
• W2889908907 cites W2193994735 @default.
• W2889908907 cites W2463937514 @default.
• W2889908907 cites W2519331325 @default.
• W2889908907 cites W2582275302 @default.
• W2889908907 cites W2617768647 @default.
• W2889908907 cites W2623263419 @default.
• W2889908907 cites W2668361924 @default.
• W2889908907 cites W2735081369 @default.
• W2889908907 cites W2754543786 @default.
• W2889908907 cites W3142447781 @default.
• W2889908907 cites W4377428302 @default.
• W2889908907 cites W84704252 @default.
• W2889908907 doi "https://doi.org/10.1016/j.hlc.2018.08.002" @default.
• W2889908907 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30262154" @default.
• W2889908907 hasPublicationYear "2019" @default.
• W2889908907 type Work @default.
• W2889908907 sameAs 2889908907 @default.
• W2889908907 citedByCount "5" @default.
• W2889908907 countsByYear W28899089072019 @default.
• W2889908907 countsByYear W28899089072020 @default.
• W2889908907 countsByYear W28899089072023 @default.
• W2889908907 crossrefType "journal-article" @default.
• W2889908907 hasAuthorship W2889908907A5003324293 @default.
• W2889908907 hasAuthorship W2889908907A5018666743 @default.
• W2889908907 hasAuthorship W2889908907A5028454371 @default.
• W2889908907 hasAuthorship W2889908907A5038067799 @default.
• W2889908907 hasAuthorship W2889908907A5052004020 @default.
• W2889908907 hasAuthorship W2889908907A5064314277 @default.
• W2889908907 hasAuthorship W2889908907A5066782203 @default.
• W2889908907 hasAuthorship W2889908907A5073216396 @default.
• W2889908907 hasAuthorship W2889908907A5078162124 @default.
• W2889908907 hasAuthorship W2889908907A5082068143 @default.
• W2889908907 hasConcept C111758988 @default.
• W2889908907 hasConcept C126322002 @default.
• W2889908907 hasConcept C198826908 @default.
• W2889908907 hasConcept C2779360546 @default.
• W2889908907 hasConcept C2779395532 @default.
• W2889908907 hasConcept C29688787 @default.
• W2889908907 hasConcept C2992686903 @default.
• W2889908907 hasConcept C519063684 @default.
• W2889908907 hasConcept C71924100 @default.
• W2889908907 hasConcept C86803240 @default.
• W2889908907 hasConcept C95444343 @default.
• W2889908907 hasConceptScore W2889908907C111758988 @default.
• W2889908907 hasConceptScore W2889908907C126322002 @default.
• W2889908907 hasConceptScore W2889908907C198826908 @default.
• W2889908907 hasConceptScore W2889908907C2779360546 @default.
• W2889908907 hasConceptScore W2889908907C2779395532 @default.
• W2889908907 hasConceptScore W2889908907C29688787 @default.
• W2889908907 hasConceptScore W2889908907C2992686903 @default.
• W2889908907 hasConceptScore W2889908907C519063684 @default.
• W2889908907 hasConceptScore W2889908907C71924100 @default.
• W2889908907 hasConceptScore W2889908907C86803240 @default.
• W2889908907 hasConceptScore W2889908907C95444343 @default.

• next